LEAP-2 Counteracts Ghrelin-Induced Food Intake in a Nutrient, Growth Hormone and Age Independent Manner.
Javier LugildeSabela CasadoDaniel BeiroaJuan CuñarroMontserrat Garcia-LavandeiraClara V AlvarezRuben NogueirasCarlos DiéguezSulay TovarPublished in: Cells (2022)
Data gleaned recently shows that ghrelin, a stomach derived peptide, and liver-expressed-antimicrobial peptide 2 (LEAP-2) play opposite roles on food intake. However, the data available with LEAP-2 in relation to in vivo studies are still very scanty and some key questions regarding the interplay among ghrelin and LEAP-2 remain to be answered. In this work, using rats and mice, we study fasting-induced food intake as well as testing the effect of diet exposure, e.g., standard diet and high fat diet, in terms of ghrelin-induced food intake. The anorexigenic effect of LEAP-2 on fasting induced food intake appears to be dependent on energy stores, being more evident in ob/ob than in wild type mice and also in animals exposed to high fat diet. On the other hand, LEAP-2 administration markedly inhibited ghrelin-induced food intake in lean, obese ( ob/ob and DIO) mice, aged rats and GH-deficient dwarf rats. In contrast, the inhibitory effect on glucose levels can only be observed in some specific experimental models indicating that the mechanisms involved are likely to be quite different. Taken together from these data, LEAP-2 emerged as a potential candidate to be therapeutically useful in obesity.
Keyphrases
- high fat diet
- insulin resistance
- growth hormone
- high glucose
- diabetic rats
- adipose tissue
- high fat diet induced
- wild type
- weight loss
- drug induced
- type diabetes
- metabolic syndrome
- physical activity
- electronic health record
- blood glucose
- computed tomography
- big data
- blood pressure
- oxidative stress
- skeletal muscle
- magnetic resonance imaging
- deep learning
- body composition
- artificial intelligence
- contrast enhanced